Data presented at WCLC showed combining RYBREVANT ®, lazertinib and chemotherapy may address the diverse resistance that emerges after disease progression on osimertinib SINGAPORE, Sept. 11, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced…

Data presented at WCLC showed combining RYBREVANT ®, lazertinib and chemotherapy may address the diverse resistance that emerges after disease progression on osimertinib SINGAPORE, Sept. 11, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced…

Shareholders are Encouraged to Vote Well in Advance of the Proxy Deadline of 1:00 p.m. (Eastern time) on September 21, 2023 Your Vote is Important! If you need assistance with voting your shares please contact Laurel Hill Advisory Group at 1-877-452-7184 or by e-mail at…

Shareholders are Encouraged to Vote Well in Advance of the Proxy Deadline of 1:00 p.m. (Eastern time) on September 21, 2023 Your Vote is Important! If you need assistance with voting your shares please contact Laurel Hill Advisory Group at 1-877-452-7184 or by e-mail at…

Grants totaling approximately $3.5 million will support Deverra’s CAR-NK and engineered myeloid cell programs in hematologic malignancies and solid tumors WEXFORD, Pa., Sept. 11, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.